TCDB is operated by the Saier Lab Bioinformatics Group

9.A.55 The TMEM205 (TMEM205) Family

Development of cisplatin resistance in cancer cells appears to be a consequence of multiple epigenetic alterations in genes involved in DNA damage repair, proto-oncogenes, apoptosis, transporters, transcription factors, etc. Shen et al. (2010) found that expression of the hypothetical transmembrane protein TMEM205 (previously known as MBC3205) is associated with cisplatin resistance. TMEM205 was first detected by functional cloning from a retroviral cDNA library made from human cisplatin-resistant (CP-r) cells. TMEM205 is predicted to be a transmembrane protein. A polyclonal antibody directed to the TMEM205 protein showed that it is located at the cell surface. Stable transfection of the TMEM205 gene confered resistance to cisplatin by approximately 2.5-fold. Uptake assays with Alexa Fluor-cisplatin showed reduced accumulation. Analysis of TMEM205 expression profiles in normal human tissues indicates a differential expression pattern with higher expression levels in the liver, pancreas, and adrenal glands (Shen et al., 2010).

The RAB8 protein has been shown to enhance TMEM205-mediated cisplatin resistance (Shen and Gottesman 2012).  Further, single nucleotide polymorphisms (SNPs) in the TMEM205 gene alter the efficacy of platinum-based chemotherapy (Wang et al. 2014).  These results all indicate that cisplatin resistance is mediated by transport, probably efflux, via TMEM205.

This family belongs to the: Copper Resistance (CuR) Superfamily.

References associated with 9.A.55 family:

Attwood, M.M., A. Krishnan, V. Pivotti, S. Yazdi, M.S. Almén, and H.B. Schiöth. (2016). Topology based identification and comprehensive classification of four-transmembrane helix containing proteins (4TMs) in the human genome. BMC Genomics 17: 268. 27030248
Ferraro, G., V. Sanfilippo, L. Chiaverini, C. Satriano, T. Marzo, A. Merlino, and D. La Mendola. (2023). Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug''s anticancer activity. Dalton Trans. [Epub: Ahead of Print] 37337706
Gallenito, M.J., T.S. Qasim, J.N. Tutol, V. Prakash, S.C. Dodani, and G. Meloni. (2020). A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(II)-drug resistance and extrusion. Metallomics 12: 1542-1554. 32789331
Heynemann, S., H. Yu, L. Churilov, G. Rivalland, K. Asadi, R. Mosher, F. Hirsch, C. Rivard, and P. Mitchell. (2021). NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. Clin Lung Cancer. [Epub: Ahead of Print] 34953676
Shen, D.W. and M.M. Gottesman. (2012). RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res 29: 643-650. 21969054
Shen, D.W., J. Ma, M. Okabe, G. Zhang, D. Xia, and M.M. Gottesman. (2010). Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol 225: 822-828. 20589834
Wang, Y., J.Y. Yin, X.P. Li, J. Chen, C.Y. Qian, Y. Zheng, Y.L. Fu, Z.Y. Chen, H.H. Zhou, and Z.Q. Liu. (2014). The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS One 9: e91967. 24643204